Medication info
S-Ol Tablet 20 mg (Olmesartan Medoxomil)

S-Ol Tablet 20 mg (Olmesartan Medoxomil)

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tablet
Manufacturer / importer
Samik Pharmaceutical Co., Ltd.
Appearance
White round film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201101022 · Approved 2011.02.28 · Insurance code 644003130

Summary

Main use
Treatment of essential hypertension
Who takes it
Adults · Children
Adult dose
<Adults> The recommended initial dose is 10 mg once daily, administered with or without food. If blood pressure is not adequately controlled at this dose, increase to 20 mg once daily. If further blood pressure reduction is required, the dose may be increased to a maximum of 40 mg once daily. The blood pressure-lowering effect is evident within 2 weeks after starting treatment, with the maximum effect occurring at approximately 8 weeks. If blood pressure is not controlled with this drug alone, it may be administered in combination with a thiazide diuretic, such as hydrochlorothiazide. To improve adherence, it is recommended that the drug be taken at the same time each day, if possible (e.g., in the morning). In patients who may have reduced effective intravascular volume (e.g., patients taking diuretics, particularly those with renal impairment), it is recommended that treatment be started at a low dose with careful monitoring of their condition. <Elderly patients> No dosage adjustment is necessary when administering this drug to patients aged 65 years or older. Although no overall differences in efficacy or safety were observed between elderly and younger patients, it cannot be ruled out that some elderly patients may have a more sensitive response. <Patients with renal impairment> The maximum dose for patients with mild to moderate renal impairment (creatinine clearance 20-60mL/min) is 20 mg once daily. <Patients with hepatic impairment> No dosage adjustment is necessary in patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10 mg once daily, which may be increased to a maximum of 20 mg daily. Use in patients with severe hepatic impairment is not recommended because there is no experience with its use in these patients.
Child dose
Safety and efficacy in pediatric patients have not been established.

Ingredients

Manufacturer
Samik Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension

  • Essential hypertension
View approved original text

Essential hypertension is a condition characterized by persistently high blood pressure without a specific cause. This medication effectively lowers blood pressure, thereby reducing the strain on the heart and blood vessels. With consistent treatment, complications can be prevented, allowing for a healthier lifestyle. It is used for the treatment of essential hypertension.

How to take

Adult dose

<Adults> The recommended initial dose is 10 mg once daily, administered with or without food. If blood pressure is not adequately controlled at this dose, increase to 20 mg once daily. If further blood pressure reduction is required, the dose may be increased to a maximum of 40 mg once daily. The blood pressure-lowering effect is evident within 2 weeks after starting treatment, with the maximum effect occurring at approximately 8 weeks. If blood pressure is not controlled with this drug alone, it may be administered in combination with a thiazide diuretic, such as hydrochlorothiazide. To improve adherence, it is recommended that the drug be taken at the same time each day, if possible (e.g., in the morning). In patients who may have reduced effective intravascular volume (e.g., patients taking diuretics, particularly those with renal impairment), it is recommended that treatment be started at a low dose with careful monitoring of their condition. <Elderly patients> No dosage adjustment is necessary when administering this drug to patients aged 65 years or older. Although no overall differences in efficacy or safety were observed between elderly and younger patients, it cannot be ruled out that some elderly patients may have a more sensitive response. <Patients with renal impairment> The maximum dose for patients with mild to moderate renal impairment (creatinine clearance 20-60mL/min) is 20 mg once daily. <Patients with hepatic impairment> No dosage adjustment is necessary in patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10 mg once daily, which may be increased to a maximum of 20 mg daily. Use in patients with severe hepatic impairment is not recommended because there is no experience with its use in these patients.

Child dose

Safety and efficacy in pediatric patients have not been established.

Precautions

This medication can cause serious harm or death to the fetus and newborn if taken during the second and third trimesters of pregnancy, so treatment should be discontinued immediately if pregnancy is confirmed. It should not be used in patients with allergies to any of the components, during pregnancy or breastfeeding, in patients undergoing kidney dialysis, in patients with severe liver disease, in patients with bile duct obstruction, in patients with certain genetic lactose intolerance, in diabetic patients taking aliskiren, or in patients with moderate or severe renal impairment. Patients with reduced blood volume or body salt may experience hypotension; hence, their condition should be carefully assessed prior to use, and appropriate measures should be taken if hypotension occurs. Caution is required for patients with severe heart failure relying on kidney function and the renin-angiotensin-aldosterone system, as renal function deterioration may occur. Patients with impaired renal function or those who have undergone kidney transplants should have their serum potassium and creatinine levels regularly monitored, and it is not recommended for patients with severe renal impairment. Patients with renovascular hypertension should be cautious due to the risk of renal function deterioration. As there is a risk of hyperkalemia, patients with heart failure or renal impairment should periodically check serum potassium levels. Special precautions are necessary for patients with aortic stenosis, mitral valve stenosis, obstructive or hypertrophic cardiomyopathy when using this medication. Patients with primary aldosteronism may not respond to this medication, hence it is not recommended for them. Dizziness may occur due to blood pressure-lowering effects; therefore, operating dangerous machinery or working at heights should be avoided. When taken with other antihypertensives, there may be an enhanced blood pressure-lowering effect; when used combined with potassium-sparing diuretics or potassium supplements, serum potassium levels can dangerously rise. Co-administration with lithium should be avoided as it can increase lithium levels and lead to toxicity. Taking this medication with non-steroidal anti-inflammatory drugs can increase the risk of renal function deterioration, hence careful monitoring of renal function is necessary. Dual blockade with angiotensin-related drugs may increase the risk of hypotension, hyperkalemia, and acute renal failure; thus, blood pressure, renal function, and electrolyte status should be meticulously observed when administering concomitantly. Use during pregnancy poses serious risks to the fetus, hence should be discontinued immediately if pregnancy is confirmed, and consideration should be given to stopping breastfeeding or the medication if adverse reactions appear in the infant during lactation. Safety and efficacy for children have not yet been established. Elderly patients may have increased drug concentration in the body, so caution is warranted during administration. Symptoms of overdose may include hypotension, palpitations, and bradycardia, requiring appropriate treatment based on symptoms. This medication does not have a carcinogenic risk even with long-term use, and it has been considered low-risk in genotoxicity tests. Possible adverse reactions during administration may include dizziness, headache, abdominal pain, muscle pain, rash, etc., with severe cases presenting as angioedema or liver function abnormalities; immediate consultation with medical personnel is necessary if such symptoms occur.

Side effects

Dizziness, chest pain, peripheral edema, vertigo, abdominal pain, indigestion, gastroenteritis, nausea, palpitations, hypercholesterolemia, hyperlipidemia, hyperuricemia, arthralgia, arthritis, myalgia, rash, facial edema, weakness, angioedema, anaphylactic reaction, vomiting, chronic malabsorption syndrome -similar intestinal disease, intestinal vascular edema, rhabdomyolysis, hyperkalemia, acute renal failure, elevated serum creatinine, hair loss, pruritus, urticaria, autoimmune hepatitis, headache, hypertension, epistaxis, upper respiratory infection, asthma, cough

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to protect it from air and moisture, and it is important to maintain a temperature between 1 to 25 degrees Celsius. Such storage will help to retain the efficacy of the medication for a longer period.

Appearance and packaging

Appearance

White round film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.